Foundation Medicine Inc (FMI) : Gilder Gagnon Howe Co scooped up 13,515 additional shares in Foundation Medicine Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 2,014,913 shares of Foundation Medicine Inc which is valued at $48,720,596.Foundation Medicine Inc makes up approximately 0.90% of Gilder Gagnon Howe Co’s portfolio.
Other Hedge Funds, Including , California State Teachers Retirement System boosted its stake in FMI in the latest quarter, The investment management firm added 3,016 additional shares and now holds a total of 28,221 shares of Foundation Medicine Inc which is valued at $682,384.Strs Ohio boosted its stake in FMI in the latest quarter, The investment management firm added 10,500 additional shares and now holds a total of 14,500 shares of Foundation Medicine Inc which is valued at $333,355. Dnb Asset Management As sold out all of its stake in FMI during the most recent quarter. The investment firm sold 12,800 shares of FMI which is valued $279,296.
Foundation Medicine Inc closed down -0.12 points or -0.50% at $24.06 with 2,17,402 shares getting traded on Thursday. Post opening the session at $23.96, the shares hit an intraday low of $23.525 and an intraday high of $24.44 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Foundation Medicine Inc reported $-0.84 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.79. The company had revenue of $28.24 million for the quarter, compared to analysts expectations of $26.72 million. The company’s revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.98 EPS.
Foundation Medicine Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies including leukemia lymphoma myeloma and various sarcomas and pediatric cancers are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.